Ignite Creation Date:
2025-12-24 @ 11:53 AM
Ignite Modification Date:
2026-01-03 @ 7:18 PM
Study NCT ID:
NCT02018861
Status:
COMPLETED
Last Update Posted:
2023-09-28
First Post:
2013-12-05
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Sponsor:
Incyte Corporation
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-09-22
Start Date Type:
ACTUAL
Primary Completion Date:
2021-04-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-04-12
Completion Date Type:
ACTUAL
First Submit Date:
2013-12-05
First Submit QC Date:
None
Study First Post Date:
2013-12-23
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2022-04-07
Results First Submit QC Date:
None
Results First Post Date:
2022-06-28
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-09-21
Last Update Post Date:
2023-09-28
Last Update Post Date Type:
ACTUAL